Главная › Рак молочной железы › Техас › Dallas
Клинические исследования Рак молочной железы в городе Dallas, TX
55 исследований по теме Рак молочной железы ищут участников в центрах в городе Dallas и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набор участниковФаза 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Набор участниковФаза 1/2
- University of Texas Southwestern, Dallas
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Набор участниковФаза 2
- Texas Oncology DFW, Dallas
- The University of Texas Southwestern Medical Center, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Набор участниковФаза 1
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Набор участниковФаза 2
- Texas Oncology, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
Набор участниковФаза 1/2
- Avenzo Therapeutics Recruiting Site, Dallas
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Набор участниковФаза 3
- Texas Oncology - DFW ( Site 8003), Dallas
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Набор участниковФаза 3
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Набор участниковФаза 3
- Texas Oncology-Dallas Presbyterian Hospital ( Site 8000), Dallas
- Parkland Health and Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0050), Dallas
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Набор участниковФаза 3
- Research Site, Dallas
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Набор участниковФаза 2
- University of Texas Southwestern Medical Center, Dallas
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Набор участниковФаза 3
- Clinical Trial Site, Dallas
- Clinical Trial Site, Dallas
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Набор участниковФаза 3
- Parkland Health and Hospital System, Dallas
- USO - Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Набор участников
- University of Texas Southwestern Medical Center, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Набор участниковФаза 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Набор участниковФаза 1
- Texas Oncology - DFW (Sammons CC), Dallas
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Набор участниковФаза 3
- UT Southwestern Medical Center at Redbird, Dallas
- University Of Texas Southwestern Medical Center, Dallas
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Набор участниковФаза 1/2
- Baylor Scott & White Research Institute -Texas Oncology, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Набор участниковФаза 3
- Texas Oncology - DFW, Dallas
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Набор участниковФаза 2
- Texas Oncology - DFW ( Site 8000), Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набор участниковФаза 1
- Mary Crowley Cancer Research, Dallas
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Набор участниковФаза 1
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Набор участниковФаза 1/2
- Texas Oncology (Worth) - USOR, Dallas
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Набор участниковФаза 1/2
- Texas Oncology - Dallas SCRI, Dallas
Susan G. Komen's ShareForCures
Набор участниковНаблюдательное исследование
- Susan G. Komen, Dallas
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Набор участниковФаза 3
- Texas Oncology DFW, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Набор участниковФаза 3
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- Mary Crowley Cancer Research, Dallas
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Набор участниковФаза 1
- University of Texas Southwestern Medical Center, Dallas
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Набор участниковФаза 3
- Texas Oncology - Dallas Presbyterian Hospital, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
- The University of Texas Southwestern Medical Center, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набор участниковФаза 1/2
- Mary Crowley Cancer Research, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Набор участниковФаза 2
- Baylor Scott & White Research Institute, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Набор участниковФаза 2
- Texas Oncology - DFW, Dallas
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
Набор участниковФаза 2
- UT Southwestern Medical Center-Dallas, Dallas
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Набор участниковФаза 1/2
- Texas Oncology, P.A., Dallas
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Набор участниковФаза 1/2
- Texas Oncology Baylor University Medical Center, Dallas
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Набор участниковФаза 2
- Parkland Hospital, Dallas
- University of Texas Southwestern Medical Center, Dallas
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Набор участниковФаза 1
- UT Southwestern Medical Center, Dallas
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Набор участниковФаза 2
- UT Southwestern Medical Center, Dallas
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Набор участниковФаза 1/2
- Next Oncology, Dallas
- UTSW Medical Center, Dallas
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Набор участниковФаза 2
- Texas Oncology- DFW, Dallas
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
Набор участников
- UT Southwestern, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Набор участниковФаза 1/2
- Research Site, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набор участниковФаза 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Набор участниковРанняя фаза 1
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Набор участниковФаза 2
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
Converting HR+ Breast Cancer Into an Individualized Vaccine
Набор участниковФаза 2
- UT Southwestern Medical Center, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Набор участниковФаза 4
- UT Southwestern Medical Center, Dallas
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Набор участниковФаза 2
- UT Southwestern Medical Center, Dallas
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Набор участниковРанняя фаза 1
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набор участниковНаблюдательное исследование
- Massive Bio SYNERGY-AI site, Dallas
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Набор участниковФаза 3
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Набор участниковФаза 1/2
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Набор участниковФаза 1
- University of Texas Southwestern Medical Center, Dallas
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Набор участниковНаблюдательное исследование
- Texas Oncology - Presbyterian, Dallas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
Исследования Рак молочной железы в других городах
- New York City, NY134 исследований
- Houston, TX126 исследований
- Boston, MA111 исследований
- Nashville, TN80 исследований
- Los Angeles, CA72 исследований
- Edison, NJ68 исследований
- St. Louis, MO64 исследований
- Durham, NC63 исследований
- Queens, NY63 исследований
- Chicago, IL58 исследований
- Philadelphia, PA56 исследований
- Baltimore, MD47 исследований
Другие исследования в городе Dallas
- Немелкоклеточный рак легкого52 исследований
- Метастатический рак42 исследований
- Сердечная недостаточность42 исследований
- Рак (все виды)37 исследований
- Рак простаты36 исследований
- Колоректальный рак33 исследований
- Ожирение30 исследований
- Рак яичников28 исследований
- Рак мочевого пузыря27 исследований
- Рак легких27 исследований
- Рак эндометрия24 исследований
- Сердечно-сосудистые заболевания23 исследований
Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.